期刊文献+

双相障碍患者高尿酸血症发生率与精神药物及血药浓度的关系 被引量:5

Incidence of hyperuricemia in patients with bipolar disorder and its relationship with psychotropic drugs and drug concentrations
下载PDF
导出
摘要 目的探讨双相障碍(bipolar disorder,BD)患者高尿酸血症(hyperuricemia,HUA)的发生率及其与精神药物、血药浓度的关系。方法回顾性纳入2252例BD患者,根据血清尿酸(uric acid,UA)水平分为HUA组和非高尿酸血症(non-hyperuricemia,NHUA)组,比较两组的人口学特征、临床特征和用药差异,分析血清UA水平与精神药物及血药浓度的关系。结果BD患者中HUA的发生率为42.94%(967例)。偏相关分析显示出院时UA水平与血锂浓度呈正相关(r=0.321,P=0.026),与丙戊酸浓度(r=-0.046,P=0.758)、奥氮平浓度(r=0.046,P=0.756)无统计学相关性。多因素线性回归显示,出院时UA水平与使用碳酸锂(β=0.130,P<0.001)、丙戊酸盐(β=0.057,P=0.001)和奥氮平(β=0.039,P=0.028)呈正相关,与使用拉莫三嗪(β=-0.034,P=0.039)呈负相关,模型的解释程度为47%(F=117.908,P<0.001)。结论BD患者HUA高发,使用碳酸锂、丙戊酸盐、奥氮平可能为其危险因素,拉莫三嗪可能为保护因素。 Objective This study aims to investigate the incidence of hyperuricemia(HUA)in patients with bipolar disorder(BD)and its relationship with psychotropic drugs and drug concentrations.Methods Two thousand two hundred and fifty-two patients with BD were included and divided into HUA group and non-hyperuricemia group(NHUA)according to the level of serum uric acid(UA).The demographic,and clinical characteristics as well as medication differences between the two groups were compared.The relationship between serum UA level and psychotropic drugs and plasma drug concentration was analyzed.Results The incidence of HU A in BD patients was 42.94%.Partial correlation analysis showed that the level of serum UA at discharge was positively correlated with the concentration of lithium(r=0.321,P=0.026),but not with the concentration of valproic acid(r=-0.046,P=0.758)and olanzapine(r=0.046,P=0.756).Multivariate linear regression showed that the level of serum UA at discharge was positively correlated with the use of lithium carbonate(β=0.130,P<0.001),valproate(β=0.057,P=0.001)and olanzapine(β=0.039,P=0.028),while was negatively correlated with the use of lamotrigine(β=-0.034,P=0.039).The interpretation degree of the model was 47%(F=117.908,P<0.001).Conclusion Patients with BD have high incidence of HU A.Lithium carbonate,valproate and olanzapine may be risk factors of HU A,while lamotrigine may be a protective factor.
作者 王威 周佳 任艳萍 李胜 谢高明 徐劲节 WANG Wei;ZHOU Jia;REN Yanping;LI Sheng;XIE Gaoming;XU Jinjie(The National Clinical Research Center for Mental Disorders&Beijing Key Laboratory of Mental Disorders,Beijing Anding Hospital Capital Medical University,Beijing 100088;Advanced Innovation Center for Human Brain Protection,Capital Medical University,Beijing 100069,China)
出处 《中国神经精神疾病杂志》 CAS CSCD 北大核心 2022年第1期40-44,共5页 Chinese Journal of Nervous and Mental Diseases
基金 国家重点研发计划(编号:2017YFC1311101) 北京市属医院科研培育计划项目(编号:PX2021070)。
关键词 双相障碍 高尿酸血症 精神药物 血药浓度 碳酸锂 丙戊酸盐 奥氮平 拉莫三嗪 Bipolar disorder Hyperuricemia Psychotropic drugs Drug concentration Lithium carbonate Valproate Olanzapine Lamotrigine
  • 相关文献

参考文献3

二级参考文献43

  • 1Decaux G, Prospert F, Namias B, et al. Hyperuricemia as a clue for central diabetes insipidus (lack of V1 effect) in the differential diagnosis of polydipsia [J]. Am J Med, 1997, 103(5) : 376-382.
  • 2Johnson G. Lithium-early development, toxicity, and renal function [J]. Neuropsychopharmacology, 1998, 19(3); 200-205.
  • 3Hensen J, Haenelt M, Gross P. Lithium induced polyuria and renal vasopressin receptor density [J]. Nephrol Dial Transplant, 1996, 11(4): 622-627.
  • 4Markowitz GS, Radhakrishnan J, Kambham N, et al. Lithium nephrotoxicity: a progressive combined glomerular and tuhulointerstitial nephropathy [J]. J Am Soc Nephrol, 2000, 11 (8): 1439-1448.
  • 5van-Gerven HA, Boer WH. Chronisehe nierfunetiestoornissen bij lithiumgebruik [Chronie renal funetion disorders during lithium use] [J]. Ned Tijdsehr Geneeskd, 2006, 150(31): 1715-1718.
  • 6HWANG Y J, DIXON SN, REISS JP, et al. Atypical antipsychotic drugs and the risk for acute kidney injury and other adverse out- comes in older adults: a population-based cohort study [J]. Ann Intern Med, 2014, 161(4): 242-248.
  • 7KASTENG F, ERIKSSON J, SENNFALT K, et al. Metabolic ef- fects and cost-effectiveness of aripiprazole versus olanzapine in schizophrenia and bipolar disorder [J]. Acta Psychiatr Scand, 2011, 124(3): 214-225.
  • 8ROJO LE, GASPAR PA, SILVA H, et al. Metabolic syndrome and obesity among users of second generation antipsychotics: a global challenge for modern psychopharmacology [J]. Pharmacol Res, 2015, 101: 74-85.
  • 9DE HERT M, DETRAUX J, VAN WINKEL R, et al. Metabolic and cardiovascular adverse effects associated with antipsychotic drugs [J]. Nat Rev Endocrinol, 2012, 8(2): 114-126.
  • 10VANCAMPFORT D, WAMPERS M, MITCHELL AJ, et al. A me- ta-analysis of cardio-metabolic abnormalities in drug naive, first-episode and multi-episode patients with schizophrenia ver- sus general population controls [J]. World Psychiatry, 2013, 12 (3): 240-250.

共引文献39

同被引文献20

引证文献5

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部